Prof Morschhauser speaks with ecancer at EHA 23 about the treating FL with rituximab added to chemoimmunotherapy.
These are interim findings, and Prof Morschhauser sets out the timeline for further data to be reported.
For more information, watch his presentation of this data at a press session here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.